What Is CagriSema?
CagriSema is Novo Nordisk's next-generation obesity treatment. It combines two peptide hormones into a single once-weekly injection: cagrilintide, a long-acting amylin analog, and semaglutide, the same GLP-1 receptor agonist found in Wegovy. The name is straightforward: Cagrilintide + Semaglutide.
The idea behind CagriSema is that semaglutide alone already produces significant weight loss. But the body has more than one appetite-regulation system. By adding cagrilintide, which targets the amylin pathway, Novo Nordisk is essentially activating two separate appetite-suppression circuits simultaneously. In clinical trials, this dual-mechanism approach produced the largest weight loss ever recorded for a combination injectable in adults with obesity.
CagriSema is not yet FDA-approved. Novo Nordisk submitted its New Drug Application in December 2025, and the FDA is expected to make a decision in late 2026, likely between October and December. If approved, it could be commercially available by late 2026 or early 2027.
Here is what the clinical data actually shows, how CagriSema stacks up against the drugs you can already get, and what men considering GLP-1 weight loss treatment need to know right now.
How CagriSema Works: Two Pathways, One Injection
To understand why CagriSema is generating so much attention, you need to understand the two hormones it targets and why combining them produces stronger results than either one alone.
The Semaglutide Component (GLP-1)
Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone your gut releases after meals. It activates receptors in the hypothalamus and hindbrain that reduce hunger at a neurological level. It also slows gastric emptying, so you feel full longer after eating, and it modulates reward-driven eating by acting on dopaminergic pathways in the brain.
The 2.4 mg dose of semaglutide in CagriSema is the same dose used in Wegovy, the standalone version that has been on the market since 2021. If you have read about semaglutide for men or compared semaglutide vs tirzepatide, you already know this pathway.
The Cagrilintide Component (Amylin)
Cagrilintide is where CagriSema introduces something genuinely new. It is a long-acting synthetic analog of amylin, a peptide hormone co-secreted with insulin from the pancreas after you eat. Natural amylin levels are often disrupted in people with obesity and type 2 diabetes.
Cagrilintide works through a fundamentally different brain circuit than semaglutide. It activates amylin receptors in the area postrema and nucleus tractus solitarius, regions in the brainstem that sit outside the blood-brain barrier and directly sense circulating hormones. Research published in 2025 confirmed that cagrilintide reduces body weight specifically through central brain amylin receptors, not merely through slowing gastric emptying.
In practical terms, amylin suppresses appetite through a parallel but distinct pathway from GLP-1. When you combine both signals, the brain receives appetite-suppression input from two different neurological circuits. The result is more comprehensive hunger reduction than either pathway achieves alone.
Think of it this way: semaglutide tells your brain you are not hungry through one set of receptors. Cagrilintide tells your brain you are not hungry through a completely different set of receptors. The appetite-reduction signals stack. In REDEFINE 1, CagriSema produced 22.7% weight loss vs 16.1% for semaglutide alone at the same dose. That 6.6 percentage point improvement comes entirely from adding the amylin pathway.
What the Clinical Trials Actually Show
CagriSema's FDA application is built on two pivotal phase 3 trials, both published in the New England Journal of Medicine in June 2025. Here is what they found.
REDEFINE 1: Adults with Obesity (No Diabetes)
This 68-week trial enrolled 3,417 adults without diabetes who had a BMI of 30 or higher, or a BMI of 27 or higher with at least one obesity-related condition. Participants were randomly assigned to receive CagriSema, semaglutide alone, cagrilintide alone, or placebo.
| Treatment | Mean Weight Loss (Adherent) | Mean Weight Loss (All Enrolled) |
|---|---|---|
| CagriSema | 22.7% | 20.4% |
| Semaglutide alone (2.4 mg) | 16.1% | 14.9% |
| Cagrilintide alone (2.4 mg) | — | 11.5% |
| Placebo | — | 3.0% |
The 22.7% weight loss among adherent participants is the largest weight reduction ever demonstrated in a phase 3 trial of an injectable peptide combination. For a 250-pound man, that translates to roughly 57 pounds lost over 68 weeks.
REDEFINE 2: Adults with Obesity and Type 2 Diabetes
This 68-week trial enrolled 1,206 adults with obesity and type 2 diabetes. CagriSema produced a mean body weight reduction of 13.7% vs 3.4% for placebo. In people with diabetes, weight loss is typically lower because the metabolic dysfunction blunts the drug's full effect. CagriSema also reduced HbA1c significantly, with 73.5% of patients reaching an HbA1c of 6.5% or below.
CagriSema vs the Competition: Head-to-Head Data
Here is where it gets interesting. In February 2026, Novo Nordisk released the results of REDEFINE 4, the first-ever head-to-head trial comparing CagriSema directly against tirzepatide, the dual GIP/GLP-1 agonist sold as Zepbound (Eli Lilly).
REDEFINE 4: CagriSema vs Tirzepatide (Zepbound)
Over 84 weeks, 809 adults with obesity received either CagriSema or tirzepatide 15 mg. The results:
| Metric | CagriSema | Tirzepatide (Zepbound) |
|---|---|---|
| Weight loss (adherent participants) | 23.0% | 25.5% |
| Weight loss (all enrolled) | 20.2% | 23.6% |
| Non-inferiority endpoint met? | No — CagriSema did not demonstrate non-inferiority | |
CagriSema lost. It did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide. Novo Nordisk's stock dropped 15 to 16 percent the day these results were announced.
That said, context matters. CagriSema's 23% weight loss is still a strong absolute result, exceeding what standard-dose Wegovy (2.4 mg) produces. The trial also tested the current CagriSema dose — Novo Nordisk is running additional trials with higher-dose combinations (REDEFINE 11, data expected in the first half of 2027) that may narrow or close the gap.
How All the Options Compare
| Drug | Mechanism | Avg Weight Loss | FDA Status | Available Now? |
|---|---|---|---|---|
| CagriSema | Amylin + GLP-1 | 22.7% | Under review | No |
| Zepbound (tirzepatide) | GIP + GLP-1 | 20–25% | Approved Nov 2023 | Yes |
| Wegovy HD (semaglutide 7.2 mg) | GLP-1 only | ~21% | Approved Mar 2026 | Yes |
| Wegovy (semaglutide 2.4 mg) | GLP-1 only | 15–17% | Approved Jun 2021 | Yes |
| Oral Wegovy (pill) | GLP-1 only (oral) | 15% | Approved Dec 2025 | Yes |
CagriSema is a genuinely powerful drug. But the "most powerful weight loss drug ever" narrative does not hold up against the head-to-head evidence. In the only direct comparison, tirzepatide (Zepbound) produced more weight loss. Both drugs represent a major step beyond standard semaglutide. If you are waiting for CagriSema because you think it will be the strongest option available, the data so far says Zepbound already outperformed it.
Side Effects: What to Expect
CagriSema's side effect profile is broadly consistent with other GLP-1 medications, with gastrointestinal symptoms being the most common. In REDEFINE 1, the breakdown looked like this:
| Side Effect | CagriSema | Placebo |
|---|---|---|
| Any gastrointestinal event | 79.6% | 39.9% |
| Nausea | 46.0% | 13.3% |
| Diarrhea | 24.5% | 12.0% |
| Vomiting | 22.1% | 4.4% |
| Constipation | 18.1% | 5.9% |
The GI side effects were described as mostly transient and mild to moderate in severity, with the majority occurring during the dose-escalation phase (the first several weeks as the dose is gradually increased) and tapering with continued use. This pattern mirrors what men experience on semaglutide and tirzepatide.
Because CagriSema activates two distinct hormonal pathways that both slow gastric emptying, the overall rate of GI side effects is higher than with semaglutide alone. Nearly 80% of participants experienced at least one GI event. This does not mean 80% experienced severe nausea — most reported mild, temporary discomfort that resolved — but it is a higher rate than standard Wegovy.
What Men Specifically Need to Know
The REDEFINE trials enrolled both men and women, and the published results do not break out men-specific outcomes. But men have several distinct considerations when evaluating any GLP-1-based weight loss treatment.
Muscle Preservation Is Non-Negotiable
The biggest body composition concern with any aggressive weight loss medication is lean mass loss. Research on semaglutide shows that without intervention, 25 to 40 percent of total weight lost can be lean mass rather than fat. This is clinically significant, especially for men over 35 who are already experiencing age-related muscle decline.
CagriSema is expected to carry the same risk. Faster, more aggressive weight loss — which CagriSema's dual mechanism produces — increases the body's tendency to catabolize muscle for energy alongside fat.
The solution is the same regardless of which weight loss medication you use:
- Resistance training at least 3 days per week. This is the single most important intervention for preserving lean mass during pharmacological weight loss.
- Protein intake of 1.6 grams per kilogram of body weight per day (minimum). For a 220-pound man, that is roughly 160 grams of protein daily. (See our GLP-1 diet guide for men.)
- Adequate sleep. Growth hormone, which supports muscle preservation, is primarily released during deep sleep. Poor sleep accelerates lean mass loss during caloric restriction.
Novo Nordisk is running REDEFINE 5, a 104-week trial of CagriSema in 400 adults with obesity that specifically includes body composition assessments. Data from this trial will be the first to show how CagriSema affects fat mass vs lean mass in a controlled setting. Until those results are available, the muscle preservation protocols above are essential.
The Testosterone Connection
For men, weight loss and testosterone are tightly linked. Excess body fat, particularly visceral fat around the midsection, suppresses testosterone production through multiple mechanisms. Fat tissue contains aromatase, an enzyme that converts testosterone to estrogen. More fat means more aromatase activity, which means lower testosterone and higher estrogen. This is one reason why men with obesity are significantly more likely to have clinically low testosterone levels.
Losing fat reverses this process. As body fat decreases, aromatase activity drops, and the body retains more of the testosterone it produces. Studies on tirzepatide and semaglutide have both shown indirect testosterone recovery proportional to the amount of fat lost. Men who lose 15 to 20 percent of their body weight on GLP-1 medications typically see meaningful improvements in total and free testosterone levels.
CagriSema's larger average weight loss could theoretically produce a stronger testosterone recovery effect. However, there is an important caveat: aggressive caloric restriction from any weight loss drug can transiently suppress testosterone in the short term by 5 to 15 percent. This dip is usually temporary and resolves as body composition improves, but it underscores why monitoring your blood work during treatment is critical.
If you are already on TRT and considering a GLP-1 or future CagriSema treatment, you will likely need your testosterone dose adjusted as your body fat drops. Lower body fat means less aromatization, which shifts your testosterone-to-estrogen ratio. Your provider should be monitoring total testosterone, free testosterone, and estradiol every 60 to 90 days during active weight loss. (Read more about GLP-1 medications and testosterone.)
FDA Timeline and Availability
Here is the current status of CagriSema as of July 2026:
- December 2025: Novo Nordisk submitted the NDA (New Drug Application) to the FDA for CagriSema for weight management in adults with obesity or overweight with at least one comorbidity.
- February 2026: REDEFINE 4 head-to-head results released — CagriSema missed non-inferiority vs tirzepatide.
- June 2026: REIMAGINE program data showed significant HbA1c reductions in type 2 diabetes patients.
- Q4 2026 (expected): FDA decision on the weight management indication. Novo Nordisk's Q1 2026 investor materials list the decision window as October through December 2026.
- Late 2026 or early 2027 (if approved): Commercial launch.
- H1 2027: REDEFINE 11 data expected (higher-dose CagriSema exploring full weight loss potential).
It is important to emphasize: an NDA filing does not guarantee approval. And even after FDA approval, insurance coverage typically lags behind by months. The early access period for CagriSema will almost certainly be self-pay, with costs estimated at $1,000 to $1,500 per month or more.
Should You Wait for CagriSema?
This is the practical question. You have been reading about CagriSema and wondering if it is worth holding off on treatment until the "best" drug arrives. Here is how to think about it.
Reasons Not to Wait
- Effective treatments exist right now. Semaglutide and tirzepatide both produce life-changing weight loss. Waiting months for a drug that has not yet outperformed what is already available means months of continued metabolic dysfunction, hormonal suppression, and health risk from excess weight.
- The head-to-head data favors tirzepatide. In the only direct comparison, Zepbound (tirzepatide) produced more weight loss than CagriSema. The drug that beat CagriSema is available today.
- Insurance coverage will take time. Even if CagriSema is approved in Q4 2026, you will likely need to self-pay at a premium for the first six to twelve months.
- Every month matters for your hormones. If excess weight is suppressing your testosterone, every month you carry that weight is another month of suboptimal hormone levels affecting your energy, mood, body composition, and long-term health.
When Waiting Might Make Sense
- You have already tried semaglutide and plateaued or did not tolerate it — CagriSema's distinct amylin pathway may work differently for your biology.
- You have significant insulin resistance or type 2 diabetes — CagriSema's dual mechanism showed strong glycemic benefits that may benefit your specific situation.
- You want to see the body composition data from REDEFINE 5 before committing to any aggressive pharmacological weight loss.
The Bottom Line for Most Men
If you are carrying significant excess weight and it is affecting your health, your hormones, or your quality of life, the best time to start treatment is now. Not after the next FDA approval. Not after the next trial readout. The medications available today produce 15 to 25 percent weight loss, dramatic improvements in metabolic health, and meaningful testosterone recovery for men who need it.
CagriSema is an important development in the weight loss landscape. It validates the concept that targeting multiple appetite-regulation pathways produces better results. But it is a drug you might switch to in the future, not a reason to delay getting healthier today.
Key Takeaways
- CagriSema combines two mechanisms — amylin (cagrilintide) and GLP-1 (semaglutide) — in a single weekly injection.
- 22.7% average weight loss in the REDEFINE 1 trial, the highest ever for an injectable peptide combination.
- Lost to tirzepatide head-to-head — in REDEFINE 4, Zepbound produced 25.5% weight loss vs CagriSema's 23.0%.
- FDA decision expected Q4 2026 — commercial availability, if approved, likely late 2026 or early 2027.
- Muscle preservation matters — resistance training and high protein intake are essential on any GLP-1 treatment, especially for men.
- Testosterone recovery is proportional to fat lost — weight loss medications indirectly boost testosterone by reducing aromatase activity.
- Effective treatments are available now — semaglutide and tirzepatide both produce transformative results without waiting for CagriSema.